Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Novatti Announces "Buy Now Pay Later" SAAS Agreement (ASX:NOV)

Highlights Sale of Buy Now Pay Later solution to power new UK entrant $300k revenue in FY19 15% investment in the client Novatti Group Limited (ASX:NOV, “Novatti”) is please...read more

Noxopharm Announces Idronoxil Confirmed as a New Immuno-Oncology Drug (ASX:NOX)

New class of immuno-oncology drug identified Activator of NK cells and CD4+ immune cells Potential to boost function of current immuno-oncology drugs. SYDNEY, April 16, 2019: Noxopharm (AS...read more

Noxopharm Announces Veyonda Chemotherapy Enhancement Program to be Expanded (ASX:NOX)

Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancers U.S. study to investigate Veyonda + doxorubicin in sarcomas CEP-2 target st...read more

Novatti Announces Expansion of China Payments Partnerships & Processing (ASX:NOV)

Highlights OpenDNA partners with Novatti for Alipay and Wechat Pay processing New channel for retail, education and tourism payments for Chinese consumers B2B partnerships continue to grow...read more

Novatti Group announces IBM World Wire network foundation member (ASX:NOV)

Highlights Novatti joins IBM World Wire network as a foundation member IBM World Wire network built on blockchain technology for faster, cheaper and real time global payments. IB...read more

Novatti Group announces $2 million Capital Raising (ASX:NOV)

Novatti Group Limited (ASX:NOV) (Novatti or Company) is pleased to announced it has received commitments via a placement to professional and sophisticated investors to raise approximately $2 million (...read more

Novatti Group announces SendFX selects Novatti as its key supplier of technology (ASX:NOV)

11 March 2019 SendFX Remittance and Cross-border payments network - strategic investment & supply agreement Highlights SendFX remittance and cross-border payments network selects N...read more

Novatti Announces Wechat Pay Extends Chinapayments.com (ASX:NOV)

Highlights Wechat Pay now available on Chinapayments.com for the payment of Australian bills Chinapayments.com sets a processing record of $696k in February Novatti Group Limited (ASX:NOV) ...read more

Noxopharm to Expedite Veyonda Clinical Program (ASX:NOX)

Internal strategic review triggered by growing confidence in Veyonda becoming a major new anti-cancer drug and the need to confirm commercial and clinical strategies Confirmed aim to develop Veyo...read more

Noxopharm Announces Combination of Veyonda plus Radiotherapy Delivers Clinical Benefits (ASX:NOX)

- Interim (12-week) DARRT-1 readout - Combination Veyonda + low-dose radiotherapy well tolerated - PSA, pain and tumour responses at higher doses - 24-week readout to indicate longevity of re...read more

Noxopharm, December 2018 Quarterly Report Appendix 4C (ASX:NOX)

Veyonda clinical program continuing on plan Imminent release of interim DARRT-1 clinical data DARRT program to be expanded and expedited based on early data LuPIN-1 data to be released mi...read more

Noxopharm Announces Principal Investigator Discusses LuPIN-1 Study (ASX:NOX)

Lu-PIN-1 Study two-thirds enrolled Study testing ability of Veyonda to boost effect of Novartis experimental drug Noxopharm to initiate LuPIN-2 study. SYDNEY, January 14, 2019: Noxopharm (...read more

Noxopharm Announces DARRT-1 Study to Advance on Basis of Positive Clinical Data (ASX:NOX)

Trial to enrol final 12 patients at 1200mg dose Based on positive safety and clinical response data Next scheduled review late-January 2019 SYDNEY, December 11, 2018: Noxopharm (ASX:NOX) a...read more

Noxopharm Announces Positive Data from CEP-1 Study of Veyonda (ASX:NOX)

Final CEP-1 data confirm tolerability of Veyonda alone and in combination with carboplatin Halt in progression of cancer growth in 50% of patients Study provides proof-of-concept for well-tol...read more

Noxopharm, 2018 Annual General Meeting Presentation (ASX:NOX)

Noxopharm at-a-glance Australian biotechnology company. Offices Sydney, New York, Hong Kong Playing to our strength.... isoflavonoid drug platform Aiming to bring Veyonda® to market as...read more

Viewing: 1 - 15 of 200 Previous | Next